Eidos Therapeutics, Inc. (EIDX) financial statements (2021 and earlier)

Company profile

Business Address 101 MONTGOMERY STREET, SUITE 2550
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 191157
Cash and cash equivalents 191157
Receivables 00
Other undisclosed current assets 52
Total current assets: 196159
Noncurrent Assets
Operating lease, right-of-use asset 4
Property, plant and equipment 10
Other noncurrent assets 31
Total noncurrent assets: 81
TOTAL ASSETS: 204160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 52
Accounts payable 32
Accrued liabilities 00
Employee-related liabilities 20
Debt 1 
Deferred compensation liability 00
Due to related parties 00
Other undisclosed current liabilities 42
Total current liabilities: 105
Noncurrent Liabilities
Long-term debt and lease obligation 21 
Long-term debt, excluding current maturities 16 
Operating lease, liability 5
Liabilities, other than long-term debt 10
Other liabilities 00
Derivative instruments and hedges, liabilities 1 
Total noncurrent liabilities: 220
Total liabilities: 325
Stockholders' equity
Stockholders' equity attributable to parent 171155
Common stock 00
Additional paid in capital 274220
Accumulated deficit (103)(65)
Total stockholders' equity: 171155
TOTAL LIABILITIES AND EQUITY: 204160

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
Revenues 27 
Cost of revenue
(Cost of Goods and Services Sold)
 (3) 
Gross profit: 24 
Operating expenses (65)(38)
Other undisclosed operating income 0 
Operating loss: (40)(38)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 3(3)
Interest and debt expense (0) 
Net loss attributable to parent: (38)(41)
Other undisclosed net income available to common stockholders, basic  1
Net loss available to common stockholders, diluted: (38)(40)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
Net loss: (38)(41)
Comprehensive loss, net of tax, attributable to parent: (38)(41)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: